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Diminished Antioxidant Activity of High-Density
Lipoprotein–Associated Proteins in Systolic Heart Failure
W.H. Wilson Tang, MD; Yuping Wu, PhD; Shirley Mann, BS; Michael Pepoy, BS;
Kevin Shrestha, AB; Allen G. Borowski, RDCS; Stanley L. Hazen, MD, PhD
Background—Diminished serum arylesterase activity, catalyzed by the high-density lipoprotein–associated
paraoxonase-1, is associated with heightened systemic oxidative stress and atherosclerosis risk. In the present study, we
sought to determine the prognostic role of serum arylesterase activity in subjects with systolic heart failure, particularly
in relation to established cardiac biomarkers.
Methods and Results—We measured serum arylesterase activity in 760 subjects with impaired left ventricular systolic
function (left ventricular ejection fraction 50%), and prospectively followed major adverse cardiac events (including
death, nonfatal myocardial infarction, and stroke) for 3 years. In our study cohort (mean age, 6411 years; 74% men;
median left ventricular ejection fraction, 35%; median creatinine clearance, 96 mg/dL), mean serum arylesterase activity
(9825 mol/L/min/mL) was lower compared with that in healthy control subjects (mean, 11526 mol/L/min/mL,
P0.01) but higher compared with advanced decompensated heart failure subjects (mean, 6922 mol/L/min/mL,
P0.01). Within our cohort, there was modest correlation between serum arylesterase activity and high-density
lipoprotein cholesterol (r0.33, P0.01) as well as B-type natriuretic peptide (r0.23, P0.01). Lower serum
arylesterase activity was a strong predictor of poorer outcomes (hazard ratio, 2.94; 95% confidence interval, 1.54, 5.62;
P0.001). After adjusting for traditional risk factors, medication use, B-type natriuretic peptide, and creatinine
clearance, lower serum arylesterase still conferred an increased risk of major adverse cardiac events at 3 years (hazard
ratio, 2.69; 95% confidence interval, 1.37 to 5.28; P0.004).
Conclusions—In patients with systolic heart failure, decreased serum arylesterase activity, a measure of diminished
antioxidant properties of high-density lipoprotein, predicts higher risk of incident long-term adverse cardiac event
independent of established clinical and biochemical risk factors.
Oxidative stress plays an important role in the pathogen-esis and progression of heart failure.1,2 Measures of
stable oxidative byproducts, including oxidized low-density
lipoproteins (LDL),1 malondialdehyde,2 isoprostanes,3 and
urinary biopyrrins,4 are increased in the setting of heart
failure. Increased oxidative stress results from an imbalance
between reactive oxygen, nitrogen, and halogenating species
and endogenous antioxidant defense mechanisms to scavenge
free radicals and their byproducts.5,6 Therefore, an imbalance
between oxidative and antioxidative mechanisms may lead to
deleterious consequences.7
Paraoxonase-1 (PON-1) is a high-density lipoprotein
(HDL)-associated glycoprotein believed to play a key role
in facilitating systemic antioxidant activities of HDL,
including the remodeling of oxidized phospholipids.8,9
PON-1 is by far the most abundant of all paraoxonases
within the vascular compartment. Numerous studies have
shown that PON-1 serves as a primary contributor to
systemic (serum) arylesterase activity (hydrolase activity
on carboxylic ester bonds such as phenyl acetate).10 Serum
arylesterase activity has been shown to have strong corre-
lations with multiple systemic measures of oxidant stress,
including multiple distinct fatty acid oxidation products
quantified by liquid chromatography with on-line stable
isotope dilution tandem mass spectrometry.10 Thus, both
human clinical investigations and studies using PON-1
knockout mice11,12 are consistent with PON-1 serving a
major antioxidant function in vivo. Herein, we examine the
potential role of HDL antioxidant activity, as monitored by
serum arylesterase activity measurements of PON-1, as a
predictor of adverse disease progression among patients
with systolic heart failure.
Methods
Study Population
The Cleveland Clinic GeneBank study is a large, prospective cohort
study conducted from 2001 to 2006 that established a well-
characterized clinical repository with data of clinical and longitudi-
nal outcomes comprised from consenting subjects undergoing elec-
tive diagnostic cardiac catheterization procedure not in the setting of
acute coronary syndrome. All GeneBank participants gave written
informed consent approved by the Cleveland Clinic Institutional
Review Board. Clinical outcomes were prospectively ascertained
over the ensuing 3 years for all subjects after enrollment. Major
adverse cardiovascular event (MACE) was defined as all-cause
mortality, nonfatal myocardial infarction, or nonfatal cerebrovascu-
lar accident after enrollment.
The present analysis included 760 consecutive subjects with stable
systolic heart failure (left ventricular ejection fraction [LVEF]50%
as determined by echocardiography, radionuclide, or contrast ven-
triculography) enrolled in GeneBank with serum samples available
for analysis. An estimate of creatinine clearance (CrCl) was calcu-
lated using the Cockcroft-Gault equation. B-type natriuretic peptide
(BNP), creatinine, and fasting blood glucose and lipid profiles were
measured on the Abbott Architect platform (Abbott Laboratories,
Abbott Park, Ill).
To examine the range of serum arylesterase activity using this
assay, we performed a cross-sectional comparison between our
cohort of stable systolic heart failure with 2 independent sets of
subjects, all prospectively enrolled, with written informed consent
approved by the Cleveland Clinic Institutional Review Board. The
first set is a cohort of 300 prospectively recruited, apparently healthy
individuals without known cardiac diseases from a health screening
program at various locations across Cleveland, Ohio. The second set
is a cohort of 73 consecutive patients with advanced decompensated
heart failure admitted to the heart failure intensive care unit for
hemodynamically guided therapy including intravenous diuretic
therapy.
Serum Arylesterase Activity Assay
Serum arylesterase activity was measured by UV spectrophotometry
in a 96-well plate format (Spectramax 384 Plus, Molecular Devices,
Sunnyvale, Calif) using phenyl acetate (Sigma-Aldrich, St Louis,
Mo) as substrate. Briefly, initial hydrolysis rates were determined at
270 nm in 50-fold diluted serum (final) in reaction mixtures
composed of 3.4 mmol/L phenylacetate, 9 mmol/L Tris hydrocholo-
ride, pH 8, and 0.9 mmol/L calcium chloride at 24°C. An extinction
coefficient (at 270 nm) of 1310 mol/L1  cm1 was used for
calculating units of arylesterase activity, which are expressed as the
amount of phenyl acetate hydrolyzed (M/min/mL) of serum. The
intra-assay and interassay coefficients of variation for performance
of arylesterase were 1.2% and 3.9%, respectively, on 20 replicates
performed on 10 different days.
Statistical Analyses
We compared baseline characteristics between subjects with high
versus low serum arylesterase activity levels by means of the Student
t test (normally distributed) or Wilcoxon rank sum test (nonnormally
distributed) for continuous variables and 2 test for categorical
variables. One-way ANOVA was used to compare serum arylester-
ase activity levels between healthy, left ventricular systolic dysfunc-
tion (LVSD), and advanced decompensated heart failure cohorts.
The Spearman correlation was performed to determine the relation-
ship between serum arylesterase activity levels and other biochem-
ical parameters. For each continuous variable, we investigated the
log-linearity assumption of Cox models by introducing a cubic spline
component. Receiver operator characteristic curve analyses in the
context of the time to event were performed to determine the optimal
cutoff at 121 mol/L/min/mL, with risk of event estimated using
5-fold cross-validation by a Cox model. Kaplan–Meier analysis with
log-rank test was used to compare the survival curves of the 2 groups
(serum arylesterase activity 121 versus 121 mol/L/min/mL).
Cox proportional hazards regression was used for time-to-event
analysis to determine hazard ratios (HR) and 95% confidence
intervals (95% CI) for MACE. Adjustments were made for individ-
ual traditional cardiac risk factors including age, sex, systolic blood
pressure, cigarette smoking, fasting cholesterol values (including
LDL and HDL cholesterol levels). Additional adjustments included
ischemic etiology, as well as medication use (including angiotensin-
converting enzyme [ACE] inhibitors, -blockers, and statin therapy),
BNP, and CrCl (both logarithmic-transformed) to predict incident
3-year MACE risks. In the case of non–log-linearity such as serum
arylesterase activity, the continuous variable was transformed into a
binary variable, the optimal cutoff value for dichotomization being
the value minimizing the prediction error in MACE event. All
analyses were performed using SAS version 8.2 (Cary, NC) and R
2.8.0 (Vienna, Austria). A probability value 0.05 was considered
statistically significant.
Results
Study Population
Table 1 describes the baseline characteristics of the subjects,
which is a relatively well-compensated patient cohort with
median LVEF of 35%, normal mean CrCl of 10041
mL/min/1.73 m2, 63% ACE inhibitor use, and 39% treated
with standing diuretic therapy. Serum arylesterase activity
levels were normally distributed, with a mean of
9825 mol/L/min/mL, which was lower than levels in the
apparently healthy control population (mean, 11526 mol/
L/min/mL, P0.01, Figure 1) but higher than levels of
hospitalized patients with advanced systolic heart failure
(mean, 6922 mol/L/min/mL, P0.01). In general, male
subjects tended to have lower serum arylesterase activity
levels than female subjects (9725 versus 10225 mol/L/
min/mL; P0.01). Compared with the GeneBank cohort, the
apparently healthy control population was younger (6411
versus 4214 years, P0.01) and had less hypertension
(72% versus 13%, P0.01) and diabetes mellitus (39%
versus 2%, P0.01). In contrast, subjects with advanced
decompensated heart failure were more likely to be male and
had lower CrCl (6835 versus 10041 mL/min/1.73 m2
P0.01) and LVEF (26% versus 35%, P0.01) than that in
the GeneBank cohort.
Serum Arylesterase Activity, Fasting Lipid Profile,
and Cardiac Biomarkers
There was modest correlation between serum arylesterase activ-
ity and HDL cholesterol (r0.33, P0.001), LDL cholesterol
(r0.20, P0.001), and triglyceride (r0.18, P0.001) levels.
Lower serum arylesterase activity levels were associated with
higher plasma BNP levels (r0.23, P0.01; Kruskal-Wallis
test across BNP quartile groups, P0.001). In contrast, weaker
correlations were observed between serum arylesterase activity
and LVEF (r0.12, P0.01). As a result, subjects with lower
serum arylesterase activity at baseline demonstrated greater
abnormalities in fasting lipid profiles as well as higher plasma
BNP levels compared with that of subjects with higher serum
arylesterase activity (Table 1).
Serum Arylesterase Levels and Major Adverse
Cardiac Outcomes
A total of 134 events (nonfatal myocardial infarction, stroke,
or death) were recorded within the 3-year period of follow-
up. As continuous variables, lower serum arylesterase activity
was associated with poorer long-term outcomes (HR for
lowering serum arylesterase activity per standard deviation
decrease, 1.32; 95% CI, 1.12 to 1.54; P0.001). This was
observed in the setting of both ischemic (HR, 1.28; 95% CI,
1.05 to 1.56, P0.013) and nonischemic (HR for lowering
serum arylesterase activity, 1.52; 95% CI, 1.11 to 2.04,
P0.008) heart failure. When stratified according to serum
arylesterase activity quartiles, subjects within the lowest 3
quartiles (116 mol/L/min/mL) demonstrated increased
risk compared with the highest quartile (HR, 1.98; 95% CI,
1.23 to 3.18; P0.005). In Kaplan–Meier analysis, serum
arylesterase activity levels below the receiver operator char-
acteristic–determined optimal cutoff level of 121 mol/L/
min/mL were associated with increased risk for development
of MACE at 3 years (HR, 2.94; 95% CI, 1.54 to 5.62;
P0.003; Figure 2). After adjusting for traditional risk
factors, medication use, BNP, and CrCl, serum arylesterase
levels below this cutoff value still maintained a 2.7-fold
increased risk in the development of future MACE (HR, 2.69;
95% CI, 1.37 to 5.28; P0.004; Table 2). To test whether
associations differed by heart failure etiology, we included an
interaction term in our Cox models between serum arylester-
ase activity and ischemic/nonischemic etiology. This was no
significant interaction, suggesting that a higher serum aryles-
terase activity maintains a 3-fold increased risk in the
development of future MACE regardless in both groups (HR,
3.03; 95% CI, 1.35 to 6.79; P0.001).
Discussion
We report for the first time there is a notable reduction in
HDL-associated antioxidant PON-1 activity (as monitored by
Table 1. Baseline Subject Characteristics
Serum Arylesterase Activity
Variable Total
121 mol/L/min/mL
(n622)
121 mol/L/min/mL
(n138) P Value
Age, y 6411 6411 6411 0.346
Male, % 74 74 73 0.800
Diabetes mellitus, % 39 40 35 0.289
Hypertension, % 72 71 76 0.270
Ischemic etiology, % 68 67 73 0.192
LDL cholesterol, mg/dL 94 (75, 116) 93 (74, 113) 108 (84, 129) 0.001
HDL cholesterol, mg/dL 32 (26, 38) 31 (26, 36) 36 (30, 45) 0.001
BNP, mg/dL 193 (86, 481) 212 (94, 505) 133 (67, 351) 0.001
LVEF, % 35 (30, 45) 35 (30, 45) 40 (30, 45) 0.110
CrCl, mL/min/1.73 m2 10041 10042 10136 0.652
Baseline medications
Aspirin, % 73 72 80 0.075
Statins, % 62 61 68 0.149
Diuretics, % 39 40 38 0.704
ACE inhibitors, % 63 64 61 0.579
-blockers, % 67 67 67 0.983
Values are expressed as meanstandard deviation or median (interquartile range).
Figure 1. Comparison of serum arylesterase activity between
healthy control subjects, patients with stable systolic heart fail-
ure, and hospitalized patients with advanced decompensated
heart failure. Probability value is for 1-way ANOVA comparison
across the 3 subgroups.
Figure 2. Kaplan–Meier analysis for long-term MACE. Probabil-
ity value is for log-rank test.
serum arylesterase activity) in stable patients with impaired
LV systolic function, as well as those admitted with advanced
decompensated systolic heart failure, when compared with
healthy control subjects. We further demonstrated a robust
association between low serum arylesterase activities and
poor long-term prognosis independent of ischemic etiology
and traditional cardiac risk factors in patients with impaired
LV systolic function undergoing cardiac evaluation. These
observations are in parallel with reports of the prognostic
value of other oxidative stress markers in patients with heart
failure but were performed on a large scale. Our findings
imply a potential importance of the HDL-associated protein
PON-1, which has established links with multiple measures
of systemic oxidant stress, as an important protective pathway
that is diminished in the setting of cardiac dysfunction.
Human studies of oxidative stress in heart failure have
focused on end-products rather than mediators of (or in this
case protectors against) the oxidative process. The potential
contribution of low HDL and low apolipoprotein A1 levels to
increased risk of incident heart failure has been demonstrated
in large epidemiology studies,13,14 although there has been
some dispute noting that coronary ischemia may be an
important confounder.15 These findings are supported by
animal studies of human apolipoprotein A1 gene transfer that
prevents the development of diabetic cardiomyopathy.16 In
patients with established heart failure, the role of low HDL
and/or low apolipoprotein A1 in predicting heart failure
events as well as mortality has been demonstrated,17–20 even
in those with nonischemic etiologies.21 Although most have
speculated the primary contribution of HDL’s favorable
effects is via its reverse cholesterol transport properties, other
anti-inflammatory, antiapoptotic, and antithrombotic effects
of HDL can also play important roles as evidenced by with its
inverse relationship with inflammatory mediators.22,23
PON-1 activity monitored via serum arylesterase activity is
a readily detectable and quantifiable process in human serum.
Much of the HDL attributed antioxidant effects reported are
now believed to be mediated by PON-1, which in the plasma
compartment exists essentially only as an HDL-associated
protein owing to the high binding affinity of PON-1 to HDL
and the ability of HDL to stabilize PON-1 activity. Low
levels of serum arylesterase activity are associated with
increased systemic measures of oxidative stress, heightened
cardiovascular disease risk,13 and increased disease severity
in other end-organ dysfunction.16,17 Instead of indirectly
measuring byproducts of oxidative stress, which is often
unstable and tedious, quantifying serum arylesterase activity
levels facilitates a direct measurement of the antioxidative
process that has been previously described in protecting
against organophosphate toxicity24 and reducing atheroscle-
rotic cardiovascular risk in both humans10,25 and animal
models.12 The broad overlap between serum arylesterase
activity levels in normal control subjects versus those with
underlying systolic heart failure may preclude the potential
for its use as a diagnostic marker for the presence of cardiac
dysfunction or heart failure. However, the ability of aryles-
terase levels to predict long-term outcomes in patients with
heart failure is intriguing, especially when the strength of risk
prediction for serum arylesterase activity appears robust, even
after adjustments for BNP and other cardiometabolic risk
factors and renal function. The strong prognostic value of
serum arylesterase activity is not linear because the lowest 3
quartiles of subjects had poorer outcomes compared with the
highest quartile. This finding may imply that there exists a
“threshold” of antioxidant activity needed. The cutoff level of
activity suggested by receiver operator characteristic curve
analyses for defining a high-risk cohort suggests a broad
systolic heart failure population may be identified as being at
risk using this biomarker. Of note, the present results also
suggest that those with relatively preserved (high) serum
arylesterase activity may also be reassured that they are in a
relatively lower risk category for long-term adverse cardiac
events.
The precise pathophysiologic mechanism of PON-1 activ-
ity in human heart failure has not been previously examined.
The expression and variability of systemic arylesterase activ-
ity over the natural history of heart failure is largely un-
known, although it is conceivable that reduced serum aryles-
terase activity can adversely contribute to disease progression
in a number of ways. The best-described mechanism is the
association between PON-1 activity and protection against
lipoprotein oxidation, thereby antagonizing progression of
atherosclerotic coronary artery disease, a major cause of heart
failure in Western societies. Another potential protective
mechanism for arylesterase activity may include the possibil-
ity for limiting microvascular dysfunction as a result of
endothelial dysfunction.26,27 Indeed, lower serum paraoxo-
nase/arylesterase activity has been reported in patients with
cardiac syndrome X,28 and genetic polymorphisms favoring
preserved paraoxonase/arylesterase are protective of micro-
vascular diseases in patients with diabetes mellitus.29 Regard-
less, the possibility that a specific antioxidative pathway,
such as catalyzed by PON-1, modulates systemic oxidative
stress in protecting heart failure progression warrants further
mechanistic investigations.
Study Limitations
Because serum arylesterase levels were only measured at a
single time-point, we were unable to examine the variability
and prognostic value of level changes over time or the impact
of different therapeutic strategies (such as ACE inhibitors or
Table 2. Cox Proportional Hazard Analysis for Diminished
Serum Arylesterase Activity on Major Adverse Cardiac Events
at 3 Years
Analysis HR (95% CI) P Value
Univariate analysis* 2.94 (1.54–5.62) 0.001
Multivariate analysis*
Model 1 (traditional risk
factorsischemic etiology)†
3.14 (1.57–6.30) 0.001
Model 2 (traditional risk
factorsmedicationsCrClBNP)‡
2.69 (1.37–5.28) 0.004
*Serum arylesterase activity levels were dichotomized at 121 mol/L/min/mL.
†Traditional risk factors include age, sex, systolic blood pressure, diabetes
mellitus, LDL cholesterol, HDL cholesterol, smoking, and ischemic etiology.
‡Medication use includes ACE inhibitors, b-blockers, and statins. CrCl and
BNP were log-transformed.
-blockers) on serum arylesterase activity. The heterogeneity
of LVEF determination (either by echocardiography, contrast
ventriculography, or radionuclide ventriculography) may
arise because not all patients in the GeneBank study had
simultaneous echocardiographic evaluation at the time of
blood sample collection. Even though the traditional “cutoff”
of LVEF for determining systolic heart failure is 40%, our
results were essentially identical when only analyzed within
the subgroup of patients defined by this criterion. The original
GeneBank protocol also did not include prospective collec-
tion of heart failure outcomes including heart failure–related
hospitalizations, cardiac transplantation, or mechanical circu-
latory assist devices. Selection bias may also be present for
those undergoing cardiac catheterization for evaluation and
management of heart failure at a tertiary care setting despite
being a common practice to rule out underlying ischemia (as
we observed a relatively large majority of patients had
ischemic etiology) and for those potentially earlier in the
disease course (evident from comparison with an advanced
decompensated heart failure cohort). The relative risks might
be smaller if heart failure–specific covariates and end points
are applied. Nevertheless, the large sample size of our patient
population together with careful phenotypic evaluation at the
time of enrollment provided a well-characterized population
of stable patients with impaired LV systolic function. Further
understanding of such antioxidative pathways is warranted
and may provide opportunities to modulate or enhance such
pathways in the setting of systolic heart failure.
Conclusions
In patients with systolic heart failure, diminished activity
levels of the antioxidant HDL-associated enzyme PON-1, as
monitored by serum arylesterase levels, predict shorter time
to develop incident long-term adverse cardiac events inde-
pendent of established clinical and biochemical risk factors.
These intriguing results provide further support for a role for
oxidative processes in the disease progression of heart failure
and for a potential antioxidant compensatory role of HDL.
Further investigations on the relationship of serum arylester-
ase activity and heart failure are warranted, as are studies
aimed at modulating PON-1 activity as a means of potentially
protecting the failing heart from disease progression.
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